Transcenta Holding Limited (Transcenta, Stock Code: 06628) has unveiled a board reshuffle set to be confirmed at the 30 June 2026 annual general meeting (AGM). The proposal introduces Dr. Hansen Xu as a non-executive director (NED) and Dr. Jun Bao as an independent non-executive director (INED), while current INEDs Dr. Kumar Srinivasan and Mr. Zhihua Zhang will resign upon the appointments taking effect.
Dr. Hansen Xu, aged 37, is vice president at Liyan Enterprise Management Consulting (Shanghai) Co., Ltd., affiliated with the Company’s substantial shareholder LAV Biosciences Fund III, L.P. His prior experience includes three years with Boston Consulting Group’s Greater China healthcare practice. Dr. Xu holds a Ph.D. in biochemistry from Cornell University.
Dr. Jun Bao, aged 59, returns to the board after previously serving as an INED (Mar 2021–Aug 2023). He is currently Chief Business Officer of Biotheus Inc. and founding/managing partner of Apuri BioVenture Limited. Dr. Bao has held senior roles at Impact Therapeutics, Shenogen Pharma, GlaxoSmithKline, Onyx Pharmaceuticals and Procter & Gamble, and brings more than three decades of combined R&D and business development experience. He is interested in 10,000 shares of Transcenta.
Both proposed directors will sign three-year appointment letters, subject to three-month termination notice. Each will receive an annual director’s fee of RMB 200,000 and may be granted share-based compensation equivalent to 30,000 ordinary shares at the Board’s discretion.
Committee adjustments, effective upon the new appointments, are as follows: 1) Dr. Bao joins the Remuneration, Audit and Nomination Committees; 2) Ms. Helen Wei Chen becomes Chairperson of the Remuneration Committee; 3) Dr. Xu becomes a member of the Remuneration Committee; 4) Dr. Xueming Qian assumes the role of Chairperson of the Nomination Committee.
Departing INEDs Dr. Srinivasan and Mr. Zhang cited increased external commitments and confirmed no disagreements with the Board.
A shareholder circular outlining the proposed director appointments and AGM notice will be dispatched in due course. Following approval, Transcenta’s Board will comprise one executive director, two NEDs and four INEDs.